Article Details
Retrieved on: 2024-02-02 13:51:47
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... Alexion, AstraZeneca Rare Disease. Results showed consistency to those in the global BridgeBio ATTRibute-CM Phase III trial (NCT03860935) ...
Article found on: www.biospace.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here